Patent details

EP1819326 Title: DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST

Basic Information

Publication number:
EP1819326
PCT Application Number:
PCT/US/2005/043044
Type:
European Patent Granted for LU
Legal Status:
Revoked
Application number:
EP058262197
PCT Publication Number:
WO/2006/058316
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST
French Title of Invention:
POSOLOGIE D'UN AGONISTE DU RECEPTEUR S1P
German Title of Invention:
DOSIERUNGSPLAN EINES S1P-REZEPTORAGONISTEN
SPC Number:

Dates

Filing date:
28/11/2005
Grant date:
02/07/2014
EP Publication Date:
02/07/2014
PCT Publication Date:
01/06/2006
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
22/08/2007
EP B1 Publication Date:
02/07/2014
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
28/11/2025
Renunciation date:
Revocation date:
28/11/2014
Annulment date:

Owner

From:
28/11/2005
 
 

Name:
Novartis AG
Address:
Corporate Intellectual Property Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Name:
Novartis Pharma GmbH
Address:
Brunner Strasse 59, 1230 Wien, Austria (AT)

Inventor

1

Name:
KOVARIK John, M.
Address:
Switzerland (CH)

2

Name:
APPEL-DINGEMANSE Silke
Address:
Switzerland (CH)

Priority

Priority Number:
631483 P
Priority Date:
29/11/2004
Priority Country:
United States (US)

Classification

Main IPC Class:
A61K 31/135;
Filing date Document type Number of pages